{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:28:16Z","timestamp":1694629696986},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/s11906-007-0009-3","type":"journal-article","created":{"date-parts":[[2007,4,25]],"date-time":"2007-04-25T16:26:36Z","timestamp":1177518396000},"page":"45-52","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mineralocorticoid receptor antagonists"],"prefix":"10.1007","volume":"9","author":[{"given":"Hari Krishnan","family":"Parthasarathy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,4,26]]},"reference":[{"key":"9_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1210\/jcem-6-2-117","volume":"6","author":"H. Selye","year":"1946","unstructured":"Selye H: The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 1946, 6:117\u2013230.","journal-title":"J Clin Endocrinol"},{"key":"9_CR2","first-page":"533","volume":"9","author":"M. Schachter","year":"2002","unstructured":"Schachter M: Aldosterone antagonism: new ideas, new drugs. Br J Cardiol 2002, 9:533\u2013537.","journal-title":"Br J Cardiol"},{"key":"9_CR3","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"C.G. Brilla","year":"1990","unstructured":"Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67:1355\u20131364.","journal-title":"Circ Res"},{"key":"9_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","volume":"25","author":"C.G. Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563\u2013575.","journal-title":"J Mol Cell Cardiol"},{"key":"9_CR5","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R. Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802\u20131810.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9_CR6","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F. Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700\u20132706.","journal-title":"Circulation"},{"key":"9_CR7","doi-asserted-by":"publisher","first-page":"17A","DOI":"10.1016\/0002-9149(93)90240-D","volume":"71","author":"D.A. Duprez","year":"1993","unstructured":"Duprez DA, Bauwens FR, De Buyzere ML, et al.: Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993, 71:17A\u201320A.","journal-title":"Am J Cardiol"},{"key":"9_CR8","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K. Swedberg","year":"1990","unstructured":"Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730\u20131736.","journal-title":"Circulation"},{"key":"9_CR9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","volume":"103","author":"C.A. Farquharson","year":"2002","unstructured":"Farquharson CA, Struthers AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002, 103:425\u2013431.","journal-title":"Clin Sci (Lond)"},{"key":"9_CR10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ki.1997.20","volume":"51","author":"T. Oikawa","year":"1997","unstructured":"Oikawa T, Freeman M, Lo W, et al.: Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997, 51:164\u2013172.","journal-title":"Kidney Int"},{"key":"9_CR11","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1067\/mhj.2002.129969","volume":"144","author":"A.D. Struthers","year":"2002","unstructured":"Struthers AD: Aldosterone: cardiovascular assault. Am Heart J 2002, 144:S2\u20137.","journal-title":"Am Heart J"},{"key":"9_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"R.S. Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004, 351:33\u201341.","journal-title":"N Engl J Med"},{"key":"9_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/hep.1840030108","volume":"3","author":"D. Mirouze","year":"1983","unstructured":"Mirouze D, Zipser RD, Reynolds TB: Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 1983, 3:50\u201355.","journal-title":"Hepatology"},{"key":"9_CR14","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/00007611-197608000-00022","volume":"69","author":"J.W. Hollifield","year":"1976","unstructured":"Hollifield JW: Failure of aspirin to antagonize the antihypertensive effect of spironolactone in low-renin hypertension. South Med J 1976, 69:1034\u20131036.","journal-title":"South Med J"},{"key":"9_CR15","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","volume":"102","author":"I. Sungaila","year":"1992","unstructured":"Sungaila I, Bartle WR, Walker SE, et al.: Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992, 102:1680\u20131685.","journal-title":"Gastroenterology"},{"key":"9_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1291\/hypres.24.99","volume":"24","author":"A. Sato","year":"2001","unstructured":"Sato A, Takane H, Saruta T: High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. Hypertens Res 2001, 24:99\u2013104.","journal-title":"Hypertens Res"},{"key":"9_CR17","doi-asserted-by":"publisher","first-page":"2 559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"M. Hayashi","year":"2003","unstructured":"Hayashi M, Tsutamoto T, Wada A, et al.: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003, 107:2 559\u20132 565.","journal-title":"Circulation"},{"key":"9_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/hrt.2003.017368","volume":"90","author":"J.E. Macdonald","year":"2004","unstructured":"Macdonald JE, Kennedy N, Struthers AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004, 90:765\u2013770.","journal-title":"Heart"},{"key":"9_CR19","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1161\/01.CIR.94.10.2566","volume":"94","author":"N. Klauber","year":"1996","unstructured":"Klauber N, Browne F, Anand-Apte B, D\u2019Amato RJ: New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Circulation 1996, 94:2566\u20132571.","journal-title":"Circulation"},{"key":"9_CR20","doi-asserted-by":"publisher","first-page":"H2491","DOI":"10.1152\/ajpheart.00840.2004","volume":"288","author":"B.S. Huang","year":"2005","unstructured":"Huang BS, Leenen FH: Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI. Am J Physiol Heart Circ Physiol 2005, 288:H2491\u20132497. Epub 2004 Dec 22.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9_CR21","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/S0021-9258(17)37833-X","volume":"254","author":"R.H. Menard","year":"1979","unstructured":"Menard RH, Guenthner TM, Kon H, Gillette JR: Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. Requirement for the 7alpha-thio group and evidence for the loss of the heme and apoproteins of cytochrome P-450. J Biol Chem 1979, 254:1726\u20131733.","journal-title":"J Biol Chem"},{"key":"9_CR22","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/0006-2952(71)90398-4","volume":"20","author":"D.R. Feller","year":"1971","unstructured":"Feller DR, Gerald MC: Interactions of spironolactone with hepatic microsomal drug-metabolizing enzyme systems. Biochem Pharmacol 1971, 20:1991\u20132000.","journal-title":"Biochem Pharmacol"},{"key":"9_CR23","first-page":"1","volume":"3","author":"M.L. Buck","year":"1997","unstructured":"Buck ML: The cytochrome P450 enzyme system and its effect on drug metabolism. Pediatr Pharmacother 1997, 3:1\u20134. Available at: http:\/\/www.healthsystem.virginia.edu\/internet\/pediatrics\/pharma-news\/MAY97.pdf. Accessed April 12, 2006.","journal-title":"Pediatr Pharmacother"},{"key":"9_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B. Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"9_CR25","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X. Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, Chatellier G, Kreft-Jais C, et al.: Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987, 60:820\u2013825.","journal-title":"Am J Cardiol"},{"key":"9_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"D.N. Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543\u2013551.","journal-title":"N Engl J Med"},{"key":"9_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.225.1.40","volume":"225","author":"D.J. Greenblatt","year":"1973","unstructured":"Greenblatt DJ, Koch-Weser J: Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1973, 225:40\u201343.","journal-title":"JAMA"},{"key":"9_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1365-2133.1988.tb02571.x","volume":"118","author":"B.R. Hughes","year":"1988","unstructured":"Hughes BR, Cunliffe WJ: Tolerance of spironolactone. Br J Dermatol 1988, 118:687\u2013691.","journal-title":"Br J Dermatol"},{"key":"9_CR29","unstructured":"Aldactone\u2014full US prescribing information. Available at: http:\/\/www.pfizer.com\/pfizer\/download\/uspi_aldactone.pdf. Accessed April 12, 2006."},{"key":"9_CR30","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(75)92645-8","volume":"1","author":"S.D. Loube","year":"1975","unstructured":"Loube SD, Quirk RA: Breast cancer associated with administration of spironolactone [letter]. Lancet 1975, 1:1428\u20131429.","journal-title":"Lancet"},{"key":"9_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00000441-197607000-00002","volume":"272","author":"R.D. Lindeman","year":"1976","unstructured":"Lindeman RD: Hypokalemia: causes, consequences and correction. Am J Med Sci 1976, 272:5\u201317.","journal-title":"Am J Med Sci"},{"key":"9_CR32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1210\/jc.2003-031337","volume":"89","author":"P. Mulatero","year":"2004","unstructured":"Mulatero P, Stowasser M, Loh KC, et al.: Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004, 89:1045\u20131050.","journal-title":"J Clin Endocrinol Metab"},{"key":"9_CR33","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"D.A. Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892\u2013896.","journal-title":"Hypertension"},{"key":"9_CR34","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","volume":"48","author":"P.O. Lim","year":"1999","unstructured":"Lim PO, Jung RT, MacDonald TM: Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999, 48:756\u2013760.","journal-title":"Br J Clin Pharmacol"},{"key":"9_CR35","first-page":"87","volume":"77","author":"M. Traina","year":"1986","unstructured":"Traina M, Vizzini GB: Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites [in Italian]. Minerva Med 1986, 77:87\u201391.","journal-title":"Minerva Med"},{"key":"9_CR36","first-page":"650","volume":"240","author":"M. de Gasparo","year":"1987","unstructured":"de Gasparo M, Joss U, Ramjoue HP, et al.: Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, 240:650\u2013656.","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR37","first-page":"514","volume":"37","author":"I.C. Coleman","year":"2002","unstructured":"Coleman IC, Reddy P, Song CJ, et al.: Eplerenone: the first selective aldosterone receptor antagonist for the treatment of hypertension. Formulary 2002, 37:514\u2013524.","journal-title":"Formulary"},{"key":"9_CR38","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1023\/A:1007597713530","volume":"17","author":"C.S. Cook","year":"2000","unstructured":"Cook CS, Zhang L, Fischer JS: Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog. Pharm Res 2000, 17:1426\u20131431.","journal-title":"Pharm Res"},{"key":"9_CR39","doi-asserted-by":"publisher","first-page":"94A","DOI":"10.1016\/S0895-7061(97)91056-6","volume":"11","author":"J. Delyani","year":"1998","unstructured":"Delyani J, Myles K, Funder J: Eplerenone (SC 66110), a highly selective aldosterone antagonist [abstract]. Am J Hypertens 1998, 11:94A.","journal-title":"Am J Hypertens"},{"key":"9_CR40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","volume":"31","author":"R. Rocha","year":"1998","unstructured":"Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31:451\u2013458.","journal-title":"Hypertension"},{"key":"9_CR41","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/en.141.10.3871","volume":"141","author":"R. Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871\u20133878.","journal-title":"Endocrinology"},{"key":"9_CR42","doi-asserted-by":"crossref","first-page":"H647","DOI":"10.1152\/ajpheart.2001.281.2.H647","volume":"281","author":"J.A. Delyani","year":"2001","unstructured":"Delyani JA, Robinson EL, Rudolph AE: Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001, 281:H647\u2013654.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9_CR43","unstructured":"Inspra description and product characteristics. Available at: http:\/\/www.fda.gov\/cder\/foi\/label\/2003\/21437sel-002_inspra_lbl.pdf and http:\/\/www.nyrdtc.nhsuk\/docs\/nde\/NDE_71_Eplerenone.pdf. Accessed April 12, 2006."},{"key":"9_CR44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"M.H. Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709\u2013716.","journal-title":"Am J Hypertens"},{"key":"9_CR45","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"J.M. Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148\u20131155.","journal-title":"J Am Coll Cardiol"},{"key":"9_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H. Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117\u2013123.","journal-title":"Hypertension"},{"key":"9_CR47","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"W.B. White","year":"2003","unstructured":"White WB, Duprez D, St Hillaire R, et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003, 41:1021\u20131026.","journal-title":"Hypertension"},{"issue":"Suppl","key":"9_CR48","first-page":"211","volume":"23","author":"W. Van Mieghem","year":"2002","unstructured":"Van Mieghem W, Von Behren V, Balazovjech I, et al.: Eplerenone is safe and effective as an add-on therapy in hypertensive patients uncontrolled with calcium channel blockers or beta blockers [abstract]. Eur Heart J 2002, 23(Suppl):211.","journal-title":"Eur Heart J"},{"key":"9_CR49","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B. Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831\u20131838.","journal-title":"Circulation"},{"key":"9_CR50","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B. Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321.","journal-title":"N Engl J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0009-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-007-0009-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0009-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0009-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T20:09:38Z","timestamp":1652904578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-007-0009-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1007\/s11906-007-0009-3","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"26 April 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}